Azurette 28 Day Shortage: What Providers and Prescribers Need to Know in 2026

Provider Briefing: Azurette 28 Day Availability in 2026

If your patients are reporting difficulty filling Azurette 28 Day prescriptions, they're not wrong. While Azurette is not listed on the FDA's official drug shortage database, real-world availability has been inconsistent across the country. This creates a practical challenge for prescribers and clinical staff who need to ensure contraceptive continuity for their patients.

This briefing covers the current availability picture, prescribing considerations, therapeutically equivalent alternatives, and tools to help your patients locate their medication. For a patient-facing overview, see the Azurette shortage update for patients.

Timeline and Background

Azurette 28 Day is a biphasic combination oral contraceptive containing Desogestrel 0.15 mg / Ethinyl Estradiol 0.02 mg (21 active tablets), 2 inert tablets, and Ethinyl Estradiol 0.01 mg (5 tablets). It is a generic equivalent of Mircette, which was discontinued by the original manufacturer (Organon). Other generic equivalents include Kariva, Viorele, Pimtrea, and Volnea.

The availability challenges with Azurette are not new. As a niche generic with a small number of manufacturers, sporadic pharmacy-level stockouts have been reported for several years. However, these have become more noticeable to patients and providers in 2025-2026 due to broader pharmaceutical supply chain pressures.

Prescribing Implications

The intermittent availability of Azurette raises several clinical considerations:

Contraceptive Continuity

Any gap in oral contraceptive use increases the risk of unintended pregnancy. When patients cannot fill their Azurette prescription, they may go without contraception rather than proactively seeking alternatives. Providers should discuss backup plans with patients during routine visits.

Therapeutic Equivalence

The following generics are FDA-rated as AB-rated therapeutically equivalent to Azurette and can be substituted without clinical concern:

• Kariva (Teva) — Desogestrel 0.15 mg / EE 0.02 mg + EE 0.01 mg, 21/2/5 regimen
• Viorele — Same formulation, 21/2/5 regimen
• Pimtrea (Amneal) — Same formulation, 21/2/5 regimen
• Volnea — Same formulation, 21/2/5 regimen

If patients are prescribed Azurette specifically, pharmacists in most states can substitute any of these equivalents unless "dispense as written" (DAW) is indicated. Consider removing DAW designations where clinically appropriate to give pharmacists maximum flexibility.

Alternative Formulations

If no biphasic Desogestrel/EE product is available, the following monophasic Desogestrel-based oral contraceptives are closely related options:

• Apri — Desogestrel 0.15 mg / EE 0.03 mg, 21/7 regimen (higher estrogen dose)
• Enskyce — Desogestrel 0.15 mg / EE 0.03 mg, 21/7 regimen

The estrogen dose difference (0.02 mg vs. 0.03 mg) is clinically meaningful for some patients, particularly those who were specifically placed on lower-estrogen formulations due to estrogen-related side effects or risk factors. Document the rationale for any switch in the patient's chart. For a comprehensive alternatives review, see the alternatives guide.

Availability Picture

The current situation can be summarized as follows:

• FDA shortage status: Not listed
• Manufacturing: Active, limited number of producers
• National availability: Variable; some regions and pharmacy chains have consistent stock while others experience gaps
• Chain pharmacy stocking: Many chains stock only 1-2 preferred generics per formulation, which may not include Azurette
• Independent pharmacies: Often more flexible and may carry or special-order Azurette

Cost and Access Considerations

Under the ACA contraceptive mandate, most insurance plans must cover at least one form of hormonal contraception at no cost to the patient. However, the specific generic covered may vary by plan:

• Some plans list Kariva or Viorele as preferred, not Azurette
• Prior authorization is generally not required for generic oral contraceptives
• Step therapy is uncommon in this drug class
• For uninsured patients, discount cards (SingleCare, GoodRx) bring the cost down to approximately $9-$15 per pack vs. a retail cash price of $50-$100+

Refer patients who are having difficulty with cost to our savings guide or suggest they explore patient assistance resources through NeedyMeds.org or RxAssist.org.

Tools and Resources for Your Practice

Several tools can help your practice manage Azurette availability issues:

Medfinder for Providers

Medfinder offers real-time pharmacy availability data that providers and clinical staff can use to direct patients to pharmacies with Azurette in stock. This is particularly useful when writing new prescriptions or handling refill issues.

Proactive Prescribing Strategies

• Prescribe by generic name without DAW to allow pharmacist substitution among equivalents
• Write for 90-day supplies when possible to reduce refill frequency
• Include alternatives on the chart so staff can quickly advise patients when Azurette is unavailable
• Flag patients on Azurette in your EHR for proactive outreach if supply issues worsen

Patient Education Materials

Direct patients to the following resources:

• How to find Azurette in stock near you
• Alternatives to Azurette
• Azurette side effects: what to expect

Looking Ahead

The niche generic oral contraceptive market is unlikely to see dramatic improvement in manufacturer diversity in the near term. Thin margins and complex regulatory requirements for combination products keep new entrants limited. Providers should plan for continued variability in Azurette availability and ensure patients are prepared with alternatives.

Consider discussing contraceptive options broadly during well-woman visits, including long-acting reversible contraceptives (LARCs) like IUDs and implants, which are not subject to pharmacy-level stockouts.

Final Thoughts

Azurette 28 Day remains available but can be difficult for patients to find due to limited manufacturers and pharmacy stocking decisions. As a provider, the most impactful steps you can take are: prescribe flexibly (avoid DAW), educate patients about equivalent alternatives, and point them to Medfinder for Providers for real-time availability data.

For a practical guide on helping patients navigate this issue, see our companion article: How to help your patients find Azurette in stock.